Precision for Medicine Accelerating Precision Oncology with Next-Gen Cancer Screening
Precision for Medicine detailed its NGS initiative which aims to improve the accuracy and speed of identifying cancer mutations in tumors.
Read MorePosted by Andy Lundin | Nov 3, 2022 | Cancer, Sequencing Systems |
Precision for Medicine detailed its NGS initiative which aims to improve the accuracy and speed of identifying cancer mutations in tumors.
Read MorePosted by Chris Wolski | Oct 11, 2022 | Breast, Prostate |
More than two years after the COVID-19 pandemic began, cancer diagnoses continue to lag behind pre-pandemic levels.
Read MorePosted by Chris Wolski | Oct 3, 2022 | Company News |
Roche has announced that Matt Sause will become CEO of Roche Diagnostics and a member of the Corporate Executive Committee on January 1, 2023.
Read MorePosted by Andy Lundin | Sep 30, 2022 | Cancer |
The USPTO granted Foresight Diagnostics a patent for the detection of MRD using its personalized phased variant detection platform.
Read MorePosted by Andy Lundin | Sep 28, 2022 | Unknown Origin & Other Cancer Types |
The Oncomine Dx Target test was approved as a CDx for a therapy targeting RET-positive thyroid cancer and RET-positive NSCLC.
Read More